SPRAVATO® offered at Motor City Medical Group is a prescription medicine, used along with an antidepressant taken by mouth to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.

What is Spravato?

Spravato is the first FDA-approved nasal spray medication, taken with an oral antidepressant, for treatment-resistant depression in adults. If you have tried two or more antidepressants without sufficient relief, Spravato might be for you. Follow the link at the bottom of this page to set a consultation with Motor City Medical Group in order to learn more about Spravato treatment.
‍
SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor. It is a first-of-its kind medicine approved by the FDA in two major depressive disorder (MDD) subpopulations with high unmet need.
‍

Regulations
‍
SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® REMS. A REMS program is in place to ensure the safety of all patients who are treated with SPRAVATO®. Motor City Medical Group operates underneath the REMS program for service implementation at our offices.
‍
The goals of the REMS are to mitigate the risks of serious adverse outcomes resulting from sedation and dissociation caused by SPRAVATO® administration, and abuse and misuse of SPRAVATO®, by: ensuring SPRAVATO® is only dispensed and administered to patients in medically supervised healthcare settings that monitor these patients, ensuring pharmacies and healthcare settings that dispense SPRAVATO® are REMS certified, ensuring patients are informed about serious adverse outcomes from dissociation and sedation and the need for monitoring, and enrolling all patients who receive treatment in an outpatient healthcare setting in a REMS registry to further characterize the risks and support safe use.
‍